Advanced Medical Solutions Group Plc · LSE:AMS

Advanced Medical Solutions — Shareholder Meeting (June 2012)

9 slides from Advanced Medical Solutions's shareholder meeting presentation, Jun 12, 2012

  1. Slide 1: Annual General Meeting: A year of progress and delivery

    ADVANCED MEDICAL SOLUTIONS GROUP PLC Annual General Meeting 12th June 2012 A year of progress and delivery

  2. Slide 2: 2011 Financial highlights

    2011 Financial highlights  Revenue up 8% to £34.4 million (2010: £31.9 million) at actual and 9% at constant currency¹  Operating profit (pre-exceptional items²) up 20% to £6.4 million (2010: £5.3 million)  Basic earnings per share (pre-exceptional items²) up 11% to 4.26p (2010: 3.83p)  Cash inf

  3. Slide 3: Advanced woundcare 2011 progress & future focus

    Advanced woundcare 2011 progress & future focus  NHS - ActivHeal (revenue up 73%) • rebrand continues to improve compliance • delivering on promise of cost savings without compromise on clinical effectiveness is resonating very strongly • continue to strengthen brand awareness - case studies, clin

  4. Slide 4: Advanced woundcare 2011 progress & future focus

    Advanced woundcare 2011 progress & future focus  Silver alginate (revenue down 2%) • gains in the US (+7%), offset by a major partner de-stocking in UK/Europe - now ended • AMS technical and clinical support continuing to drive partner ability to gain market share  Winsford facility delivering fur

  5. Slide 5: Wound closure & sealants 2011 progress & future focus

    Wound closure & sealants 2011 progress & future focus  LiquiBand  – USA • end market sales increased more than threefold in 2011 compared with 2010 • LiquiBand  achieved a full year market volume share of  5% in the hospital market  8% in the alternative site market • ex-factory revenues at sim

  6. Slide 6: Wound closure & sealants 2011 progress & future focus

    Wound closure & sealants 2011 progress & future focus  LiquiBand  – other markets • non US markets up 13% year-on-year • small but encouraging sales in both Japan and Canada • regulatory approval process underway in China & Russia  LiquiBand ® - next generation products • focus on obtaining Liqui

  7. Slide 7: Acquisition strategy: Resorba transaction rationale

    Acquisition strategy Resorba transaction rationale • Global wound care partner base • Surgical sales force and expertise • Global regulatory expertise • Collagen and suture technologies • Wound care dressings • Access to dental market • LiquiBand®, ActivHeal® • GENTA-COLL®, PARASORB®, PARASORB Sombr

  8. Slide 8: Acquisition Strategy - integration planning

    Aquisition Strategy - integration planning Phase 1 activity Q1 Q2 Q3 Q4 LiquiBand® Flex launch in Germany Rep Training Launch LiquiBand® launch in Czech Republic Rep training Launch Russian clinical study LiquiBand® regulatory approval Russia Regulatory preparation Market approval Launch and product

  9. Slide 9: Outlook

    Outlook  2012 has started well and promises to be an exciting year for AMS Group  AMS Group brands expected to be over 50% of revenue in 2012  LiquiBand expected to gain further market share in the US  RESORBA commercial synergies on track to be earnings enhancing in first year  Exciting Group

Advanced Medical Solutions Group — Shareholder Meeting (June 2012) on 6ix